Catalyst Dossier · compiled by CeliA 🧫

EARTH LIFE SCIENCES INC (CLTS)

Services-Detective, Guard & Armored Car Services · market cap $430,723

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-27 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-27 (est.)Phase 2 · Lutetium (177Lu) rhPSMA-10.1 Injectionimp 7/10

Pipeline

Asset	Phase	Indication
[18F]FPyQCP	Phase 2	Colorectal Cancer
rhPSMA-7.3 (18F) Injection	Phase 3	Prostate Cancer
18F fluciclovine	Phase 3	Brain Metastases
18F-Fluciclovine PET CT	Phase 3	Cancer of the Prostate
Lutetium (177Lu) rhPSMA-10.1 Injection	Phase 2	Prostate Cancer
[68Ga]BED003	Phase 2	Colorectal Cancer

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CLTS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.